139 related articles for article (PubMed ID: 38142203)
41. Plasma cell morphology in multiple myeloma and related disorders.
Ribourtout B; Zandecki M
Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
[TBL] [Abstract][Full Text] [Related]
42. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders.
Witzig TE; Timm M; Larson D; Therneau T; Greipp PR
Br J Haematol; 1999 Jan; 104(1):131-7. PubMed ID: 10027725
[TBL] [Abstract][Full Text] [Related]
43. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
45. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology.
Cannizzo E; Bellio E; Sohani AR; Hasserjian RP; Ferry JA; Dorn ME; Sadowski C; Bucci JJ; Carulli G; Preffer F
Cytometry B Clin Cytom; 2010 Jul; 78(4):231-8. PubMed ID: 20198608
[TBL] [Abstract][Full Text] [Related]
46. Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.
Perez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Garcia-Marcos MA; Moreno I; Dominguez M; Galende J; Heras N; Gonzalez MI; San Miguel JF; Orfao A;
J Biol Regul Homeost Agents; 2004; 18(2):161-5. PubMed ID: 15471221
[TBL] [Abstract][Full Text] [Related]
47. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
48. Measurable disease evaluation in patients with myeloma.
Roshal M
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
[TBL] [Abstract][Full Text] [Related]
49. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
[TBL] [Abstract][Full Text] [Related]
50. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
[TBL] [Abstract][Full Text] [Related]
51. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Paiva B; Corchete LA; Vidriales MB; Puig N; Maiso P; Rodriguez I; Alignani D; Burgos L; Sanchez ML; Barcena P; Echeveste MA; Hernandez MT; García-Sanz R; Ocio EM; Oriol A; Gironella M; Palomera L; De Arriba F; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Lahuerta JJ; Blade J; Orfao A; Mateos MV; San Miguel JF;
Blood; 2016 Apr; 127(15):1896-906. PubMed ID: 26755711
[TBL] [Abstract][Full Text] [Related]
52. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
[TBL] [Abstract][Full Text] [Related]
53. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
54. Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach.
Rai S; Das N; Gupta R; Kumar L; Sharma A; Singh S; Prajapati VK
Int J Lab Hematol; 2023 Apr; 45(2):179-186. PubMed ID: 36403963
[TBL] [Abstract][Full Text] [Related]
55. Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry.
Clichet V; Harrivel V; Delette C; Guiheneuf E; Gautier M; Morel P; Assouan D; Merlusca L; Beaumont M; Lebon D; Caulier A; Marolleau JP; Matthes T; Vergez F; Garçon L; Boyer T
Br J Haematol; 2022 Mar; 196(5):1175-1183. PubMed ID: 34730236
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.
Soh KT; Tario JD; Wallace PK
Clin Lab Med; 2017 Dec; 37(4):821-853. PubMed ID: 29128071
[TBL] [Abstract][Full Text] [Related]
57. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
58. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
59. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
Bezdekova R; Jelinek T; Kralova R; Stork M; Polackova P; Vsianska P; Brozova L; Jarkovsky J; Almasi M; Boichuk I; Knechtova Z; Penka M; Pour L; Sevcikova S; Hajek R; Rihova L
Br J Haematol; 2021 Oct; 195(1):95-107. PubMed ID: 34500493
[TBL] [Abstract][Full Text] [Related]
60. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
Puig N; Paiva B; Lasa M; Burgos L; Perez JJ; Merino J; Moreno C; Vidriales MB; Toboso DG; Cedena MT; Ocio EM; Lecumberri R; García de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Pérez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Prosper F; Martinez-Lopez J; Lecrevisse Q; Verde J; Mateos MV; Lahuerta JJ; Orfao A; San Miguel JF
Leukemia; 2019 May; 33(5):1256-1267. PubMed ID: 30542145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]